10.29.26 -- Measuring The Success Of A Technology Transfer

This collaboration demonstrates how a partnership-driven approach, combined with technical expertise, can deliver scalable, efficient, and reliable manufacturing solutions.

Outsourced gene therapy programs suffer from fragmented, lagging visibility across CDMO networks, and a real-time integrated operating model unifies execution, governance, and risk data.

Discover how solvent‑free, solid‑state stress testing speeds degradation studies, yields realistic impurity profiles, and provides earlier, material‑efficient insight into drug stability and risk.

Onshoring biomanufacturing operations is an increasingly common decision. While a mid-phase tech transfer from international to domestic CDMO can be complex, the right partner can ensure success.

Advanced Fill-Finish Technologies enable precise injectable drug manufacturing, maximizing yield, ensuring compliance, and supporting seamless scale-up from clinical production to commercial supply.

Platform-based manufacturing uses standardized, pre-qualified workflows and analytics that reduce variability, simplify regulatory submissions, and accelerate the path to commercial success.

Biopharmaceutical supply chain volatility is at an all-time high. To navigate this complexity, CDMOs must prioritize robust sourcing strategies and proactive vendor management.